Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)

Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news